Medtronic ICD Sales Better Than Expected, But Some Share Goes To St. Jude
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's sales of implantable cardioverter defibrillators beat analyst expectations in the most recent fiscal quarter despite lingering fall-out from the firm's October Fidelis ICD lead recall
You may also be interested in...
St. Jude Medical Gains Market Share, Increases Outlook On Strong ICD Sales
St. Jude Medical took another two to three points of global implantable cardioverter defibrillator market share in the first half of the year, on the back of 40 ICD and pacemaker product launches in the past two years, the company said July 16
St. Jude Medical Gains Market Share, Increases Outlook On Strong ICD Sales
St. Jude Medical took another two to three points of global implantable cardioverter defibrillator market share in the first half of the year, on the back of 40 ICD and pacemaker product launches in the past two years, the company said July 16
Endeavor Stent’s Debut Drives 22% Growth In Medtronic Cardiovascular Biz
Medtronic's Endeavor zotarolimus-eluting coronary stent captured over 20% of the U.S. drug-eluting stent market by the tail end of the firm's fiscal fourth quarter (ended April 25), the company reported May 20